(Total Views: 447)
Posted On: 12/07/2021 11:15:56 AM
Post# of 145882
Apparently, they have developed their own researched, based on all public information available. The percentage points are small. Therefore, I don't think they had much information available. There have been some papers published, in the last couple of years, referencing Leronlimab in cancer treatment. Some of these papers are starting to show peer review and are being referenced for treatment options. Happy hunting! I am happy to find this stuff that shows almost everything Leronlimab, is used on, is showing some efficacy. Amazing!
"GlobalData’s Investigative News team reviews data generated by an in-house model that combines machine learning and its proprietary algorithm. Likelihood of Approval (LoA) provides the probability of a drug in securing market authorization; Phase Transition Success Rate (PTSR) indicates the probability of a drug advancing to the next stage of development. The model uses data points from individual drugs, clinical trials, regulatory milestones, company, and financial databases."
"GlobalData’s Investigative News team reviews data generated by an in-house model that combines machine learning and its proprietary algorithm. Likelihood of Approval (LoA) provides the probability of a drug in securing market authorization; Phase Transition Success Rate (PTSR) indicates the probability of a drug advancing to the next stage of development. The model uses data points from individual drugs, clinical trials, regulatory milestones, company, and financial databases."
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)